Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Breast Neoplasms 1324Neoplasms 982Carcinoma, Non-Small-Cell Lung 860Prostatic Neoplasms 724Colorectal Neoplasms 666Lung Neoplasms 551Leukemia, Myeloid, Acute 475Neoplasm Metastasis 434Pancreatic Neoplasms 419Carcinoma, Hepatocellular 407Multiple Myeloma 396Ovarian Neoplasms 392Stomach Neoplasms 379Recurrence 364Squamous Cell Carcinoma of Head and Neck 325Melanoma 294Brain Neoplasms 287Uterine Cervical Neoplasms 283Triple Negative Breast Neoplasms 271Glioblastoma 264Head and Neck Neoplasms 263Precursor Cell Lymphoblastic Leukemia-Lymphoma 254Endometrial Neoplasms 234Lymphoma 228Rectal Neoplasms 222Esophageal Neoplasms 222Sarcoma 213Carcinoma, Renal Cell 203Colonic Neoplasms 194Lymphoma, Non-Hodgkin 191

Interventions

venetoclax 1pomalidomide 1ixazomib 1daratumumab 1Dexamethasone 1Calcium Dobesilate 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Interventional × Proteostasis Deficiencies × Clear all
NCT05451771 2025-07-08

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Columbia University

Phase 1/2 Recruiting
53 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Proteostasis Deficiencies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡